Advisory Services Network’s Cyclerion Therapeutics CYCN Stock Holding History

Advisory Services Network’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$4	–	1940
2023 Q1	$4	Hold	1	–	–	﹤0.01%	3980
2022 Q4	$7	Buy	+1	New	+$12	﹤0.01%	3986
2021 Q3	–	Sell	-1	Closed	–	–	1812
2021 Q2	$0	Buy	+1	New	+$63	﹤0.01%	3597
2021 Q1	–	Sell	-1	Closed	–	–	1652
2020 Q4	$0	Hold	1	–	–	﹤0.01%	3380
2020 Q3	$0	Buy	+1	New	+$114	﹤0.01%	3563
2020 Q2	–	Sell	-1	Closed	–	–	1387
2020 Q1	$0	Buy	+1	New	+$71	﹤0.01%	3075

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Advisory Services Network's CYCN Position: Q2 2023 in Review

Advisory Services Network sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 1 share — an estimated $4 sold.

Advisory Services Network first reported a position in CYCN in Q1 2020 and held it in 6 quarters. The position peaked at $7 in Q4 2022. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

Advisory Services Network reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
Advisory Services Network sold 1 Cyclerion Therapeutics share in Q2 2023, an estimated $4.
Advisory Services Network first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 6 quarters.
Advisory Services Network's Cyclerion Therapeutics position peaked at $7 in Q4 2022.
18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on Advisory Services Network's 13F filing for Q2 2023, filed 9 Aug 2023.